Ask AI
ProCE Banner Activity

Expert Perspectives and Insights on ADC-Associated Adverse Events in Patients With Breast and Lung Cancers

Clinical Thought

In this commentary, experts explore the adverse events associated with ADCs used to treat patients with breast and lung cancers along with strategies to manage and mitigate them ensuring optimal patient care.

Released: December 29, 2025

Continue Activity View Activity

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with solid tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the mechanisms of action, therapeutic targets, and clinical trial data supporting the use of ADCs in treating solid tumors to guide patient-specific treatment decisions​

  • Implement proactive monitoring and evidence-based protocols for managing ADC-related TRAEs, including early identification and appropriate intervention strategies for high-risk adverse events​

  • Design patient-centered education and interprofessional communication plans that promote timely ADC-related TRAEs recognition and encourage urgency in reporting symptoms

Disclosure

Primary Author

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Catalyst, Janssen, Jazz, Lilly, Merck, Pfizer.